RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Syreeta Tilghman to Female

This is a "connection" page, showing publications Syreeta Tilghman has written about Female.
Connection Strength

0.384
  1. Patel JR, Banjara B, Ohemeng A, Davidson AM, Bou? SM, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 2023 Mar 28; 15(7).
    View in: PubMed
    Score: 0.057
  2. Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Bou? SM, Burow ME, Khupse R, Tilghman SL. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. Int J Mol Sci. 2022 Mar 07; 23(5).
    View in: PubMed
    Score: 0.053
  3. Walker RR, Gallegos KM, Bratton MR, Lemieux KP, Zhang K, Wang G, Davidson AM, Tilghman SL. Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade. Anticancer Res. 2021 Feb; 41(2):583-599.
    View in: PubMed
    Score: 0.049
  4. Gupta A, Gupta G, Mehta RR, Ivancic DZ, Walker RR, Patel JR, Gallegos KM, Davidson AM, Khan SA, Mehta RG, Tilghman SL. A novel and cost-effective ex vivo orthotopic model for the study of human breast cancer in mouse mammary gland organ culture. Biol Open. 2020 05 29; 9(5).
    View in: PubMed
    Score: 0.047
  5. Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Bou? SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010010.
    View in: PubMed
    Score: 0.034
  6. Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, Zhang Q, Wang G. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013 Sep; 12(9):2440-55.
    View in: PubMed
    Score: 0.029
  7. Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME. Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer. J Health Care Poor Underserved. 2013 Feb; 24(1 Suppl):36-46.
    View in: PubMed
    Score: 0.028
  8. Ferguson DT, Taka E, Tilghman SL, Womble T, Redmond BV, Gedeon S, Flores-Rozas H, Reed SL, Soliman KFA, Kanga KJW, Darling-Reed SF. The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant Breast Epithelial (MCF-10AT1) Cells. Int J Mol Sci. 2024 Jan 11; 25(2).
    View in: PubMed
    Score: 0.015
  9. Darling-Reed SF, Nkrumah-Elie Y, Ferguson DT, Flores-Rozas H, Mendonca P, Messeha S, Hudson A, Badisa RB, Tilghman SL, Womble T, Day A, Jett M, Hammamieh R, Soliman KFA. Diallyl Sulfide Attenuation of Carcinogenesis in Mammary Epithelial Cells through the Inhibition of ROS Formation, and DNA Strand Breaks. Biomolecules. 2021 09 06; 11(9).
    View in: PubMed
    Score: 0.013
  10. Williams MD, Nguyen T, Carriere PP, Tilghman SL, Williams C. Protein Kinase CK2 Expression Predicts Relapse Survival in ERa Dependent Breast Cancer, and Modulates ERa Expression in Vitro. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010036.
    View in: PubMed
    Score: 0.009
  11. Payton-Stewart F, Tilghman SL, Williams LG, Winfield LL. Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells. Biochem Biophys Res Commun. 2014 Aug 08; 450(4):1358-62.
    View in: PubMed
    Score: 0.008
  12. Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved. 2013 Feb; 24(1 Suppl):104-11.
    View in: PubMed
    Score: 0.007
  13. Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PLoS One. 2012; 7(11):e49067.
    View in: PubMed
    Score: 0.007
  14. Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-a)-positive breast cancer cells. Exp Cell Res. 2011 Nov 01; 317(18):2573-81.
    View in: PubMed
    Score: 0.006
  15. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
    View in: PubMed
    Score: 0.006
  16. Zimmermann MC, Tilghman SL, Bou? SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME. Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J Pharmacol Exp Ther. 2010 Jan; 332(1):35-45.
    View in: PubMed
    Score: 0.006
  17. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010 Jun; 121(2):293-300.
    View in: PubMed
    Score: 0.005
  18. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):884s-8s.
    View in: PubMed
    Score: 0.004
  19. Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol. 1998 Nov; 67(4):293-304.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support